Zusammenfassung
Zu den sicheren und reversiblen Verhütungsmethoden bei der Frau zählen heute in erster Linie die orale Kontrazeption und die Inträuterinspirale. Für den Mann steht heute außer Kondom und Sterilisation noch keine vergleichbare Methode zur Verfügung.
Chapter PDF
Similar content being viewed by others
Literatur
Allen WM, Wintersteiner O (1934) Science 80: 190
Andolesk L et al (1983) Influence of oral conttraceptives on the incidence of premalignant and malignant lesions of the cervix. Contraception 28: 505–519
Alvarez F, Brache E, Fernandez B et al (1988) New insights on the mode of action of intrauterin contraceptive devices in women. Fertil Steril 49: 768–773
Alza Corporation (1977) The progestasert. Intrauterine progesterone contraceptive system release 65 pg/day progesterone for one year. Alza Product Information, Palo Alto
Arbeitsgruppe NFP, Bonn (1987) Natürlich und sicher, 44. Ehrenwirth, München
Arbeitskreis „Intrauterinpessare“ (1993) in Zusammenarbeit mit Nourypharma GmbH. Im Konsens getragen von: Dr. U. J. Koch, Berlin; Prof. P. Tauber, Siegen; Prof.H. Wagner, Minden
Arbeitskreis „Teenager-Sprechstunde“ in Zusammenarbeit mit der Organon GmbH (1991) Junge Mädchen in der gynäkologischen Sprechstunde
Austin, H, Louv WC, Alexander WJ (1984) A case-control study of spermicides and gonorrhea. JAMA 251 /21: 2822–2824
Baker RF, Sherwin RP, Bernstein GS, Nakamura RM, Voeller B, Coulson AH (1988) Precautions when ligthningstrikes during the monsoon. The effect of ozone on condoms. JAMA 260 /10: 1404–1405
Barlow D (1977) The condom and gonorrhoea. Lancet 2: 811–812
Bauer HA (1984) Intrauterinpessar. Eur. Patent Office No. 0.100.924 Al, February 22, 1984
Baulieu EE (1989) Contragestion an dother clinical applications of RU 486, an antiprogesterone at the receptor. Science 245 /4924: 1351–1357
Beral V et al (1988) Oral contraceptive use and malignancies of the genital tract. Lancet 2: 1331–1335
Bickenbach W, Paulikovics E (1944) Hemmung der Follikelreifung durch Progesteron bei der Frau. Zentralbl Gynäkol 68 /4
Billings EL, Westmore A (1981) The Billings method: controlling fertility without drugs or devices. Allen Lane, London
Billings EL, Billings JJ, Brown JB, Burger HG (1972) Hormonal changes accompanying ovulation. Lancet 1: 282–284
Blume A (1987) Verhüten oder Schwangerwerden. Rowohlt, Reinbek
Boehringer Information (1984) Boehringer Diagnostica
Booth M et al (1989) Risk factors for ovarian cancer: a case-control study. Br J Cancer 60: 592–598
Brinton LA, Fraumeni JF (1986) Epidemiology of uterin cervical cancer. J Chronic Diseases 39: 1051–1065
Brinton LA (1991) Oral contraceptives and cervical neoplasia. Contraception 43: 581–595
Brinton LA, Huggins GR, Lehmandt F (1986) Long-term use of oral contraceptives and risk of invasive cervical cancer. Int J Cancer 38: 339–344
Brinton LA et al (1990) Parity as a risk factor for cervical cancer. Am J Epidemiol 130: 486–496
Brock KE et al (1989) Sexual, reproductive and contraceptive risk factors for carcinoma in situ of the uterin cervix in Sydney. Med J Aust 150: 125–130
Bruckner K, Hampel B, Johnson U (1960) Darstellung und Eigenschaften monohalogenierter 3-Keto-4,6-dienosteroide. Chem Ber 94: 1225
Bustos-Obregon E, Courot M, Flechon JE, Hochereaude-Reviers MT, Holstein AF (1975) Morphological appraisal of gametogenesis. Spermatogenic process in mammals with particular reference to man. Andrologia 7: 141–163
Butenandt A, Westphal U, Hohlweg W (1934) Über das Corpus luteum. Hoppe-Seylers Z Physiol Chem 227: 84–98
Cancer and Steroid Hormone Study (1986) Oral contraceptive use and the risk of breast cancer. New England journal of medicine 315: 405–411
Cancer and Steroid Hormones Study (1987 a) The reduction in risk of ovarian cancer associated with oral contraceptive use. N Engl J Med 316:650
Cancer and Steroid Hormones Study (1987b) Combination oralcontraceptive use and the risk of endometrial cancer. JAMA 257: 796
Casagrande JT, Louie EW, Pike MC et al (1979) “Incessant ovulation” and ovarian cancer. Lancet 2:170–173
Celentano DD et al (1987) The role of contraceptive use in cervical cancer: the Maryland cervical cancer case-control study. American journal of epidemiology 126: 592–604
Chi I (1993) The safety and efficacy issues of progestin-only oral contraceptives. An epidemiologic perspective. Contraception 47: 1–21
Chilvers C et al (1987) Cervical adenocarcinoma and oral contraceptives. Br Med J 295: 1446–1447
Chiozza E (1985) United States Patent No. 4.553.536, November 19, 1985
Clarke AE, Hatcher J, McKeown-Eyssen GE, Lickrish GM (1985) Carvical dysplasia: association with sexual behavior, smoking and oral contraceptive use? Am J Obstet Gynecol 151: 612
Cramer DW, Schiff I, Schoenbaum SC et al (1985) Tubal infertility and the intrauterine device. N Engl J Med 312: 941–947
Coeling Bennink HJT et al (1990) First results of multicentre pilot efficacy study with a contraceptive vaginal ring releasing ethinylestradiol and 3-ketodesogestrel. Advances in Contraception 6: 293
Conant MA, Spicer DW, Smith CD (1984) Herpes simplex virus transmission: Condom studies. Sex Transm Dis 11 /2: 94–95
Conant M, Hardy D, Sernatinger J, Spicer D, Levy JA (1986) Condoms prevent transmission of AIDS-associated retrovirus. [Letter] JAMA 255 /13: 1706
Cramer DW, Hutchison GB, Welch WR et al (1982) Factors affecting the association of oral contraceptives and ovarian cancer. N Engl J Med 307: 1047–1051
Cuzick J et al (1989) A case-control study of cervix cancer in Singapore. British journal of cancer 60: 238–243
Daling JR, Weiss NS, Metch BJ et al (1985) Primary tubal infertility in relation to the use of an intrauterine device. N Engl J Med 312: 937–941
Dallenbach-Hellweg G (1984) On the origin and histological structure of adenocarcinoma in women under 50 years of age. Pathol Res Pract 179: 38–50
Darriw, WW (1989) Condom use and use-effectiveness in high-risk populations. Sex Transm Dis 16 /3: 157–160
Defoort P (1985) An Appraisal of the risk of 1UD-related genital infections. In: Zatuchni GE, Goldsmith A, Sciarra JJ (eds) Intrauterine contraception: advances and future prospects. Harper u. Row, Philadelphia, pp 390–397
Delgado-Rodriguez M et al (1992) Oral contraceptives and cancer of the cervix uteri: A meta-analysis. Acta Obstet Gynecol Scand 71: 368–376
Deutsche Gesellschaft für Senologie (1989) Vorschläge der Arbeitsgruppe „Hormonsubstitution in der Postmenopause nach Mammkarzinom“ Gynäkologie und Geburtshilfe 4, Demeter Verlag
Diczfalusy E (1991) Fertility regulation, reproductive health and our common future. In: Runnebaum B, Rabe T, Kiesel L (eds) Female contraception and male fertility regulation. Partheno, Casterton, pp 7–22
Diczfalusy E (1992) Contraceptive prevalence and the 1990s — a critical issue, a critical decade. Scherings Lecture’s Publ, Berlin
Djerassi C (1980) The politics in contraception. Norton, New York
Djerassi C, Miramontes L, Rosenkranz G, Sandheimer F (1954) Synthesis of 19-nor-17-a-ethyltestosterone and 19-nor-17-amethyltestosterone. J Am Chem Soc 76: 4092
Dmowski WP, Kapetanakis E, Scommegna A (1980) Contraceptive effect of intrauterine estriol delivery systems in rabbits and baboons. Contracept Deliv Syst 1: 11–16
Doering G, Baur S, Frank P et al (1986) Ergebnisse einer representativen Umfrage zum Familienplanungsverhalten in der Bundesrepublik Deutschland 1985. Geburtshilfe Frauenheilkd 46 /12: 892–897
Ebeling K, Nischan P, Schindler C et al (1987) Use of oral contraceptives and risk of invasive cervical cancer in previously screened women. Int J Cancer 39: 427–430
Edelman DA, Berger GS, Keith LG (eds) (1979) Intrauterine devices and their complications. Nijhoff, The Hague, pp 222–231
Elia D, Belaisch J (1985) Worldwide results of Gyne-T 380. Contracept Fertil Sex 13: 973–978
Emans SJ, Grace E, Woods ER et al (1987) Adolescents’ compliance with the use of oral contraceptives. JAMA 257 /24: 3377–3381
Eser A, Koch HG (1987) Rechtsfragenbei der gynäkologischen Betreuung minderjähriger Patientinnen In: Huber A, Hiersche HD (Hrsg) Praxis der Gynäkologie im Kindes-und Jugendalter, 18ff.
Fathalla MF (1992) Reproductive health in the world: two decades of progress and the challenge ahead. In: WHO (ed) Biennial Report 1990–1991. Special 20th anniversary issue. WHO, Geneva
Fernholz E (1934) Zur Synthese des Corpus luteum-Hormons (Vorläufige Mitt.). Ber Dtsch Chem Ges 67: 1855
Filshie M, Guillebaud J (eds) (1989) Contraception. Science and practice. Butterworths, London
Fox CL, Modak S, Reemtsma K (1986) Infection-resistant materials and methods of making same through use of nalidixic acid derivatives. United States Patent No. 4.563.485, Jan. 7, 1986
Free MJ, Skiens EW, Morrow MM (1980) Relationship between condom strength and failure during use. Contraception 22 /1: 31–37
Free MJ, Hutchings J, Lubis F, Natakusumah R (1986) An assessment of burst strength distribution data for monitoring quality of condom stocks in developing countries. Contraception 33 /3: 285–299
Gerstman B, Burt (1991) Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 133: 33–36
Gibor Y (1980) Intrauterine contraception with the Progestasert System. In: Hafez ES, Van Os WA (eds) Medicated intrauterine devices. Nijhoff, Amsterdam, pp 146–149
Gibson JW, Dunn RL, Perkins BH, Scommegna A (1985) Development of a fibrous IUD delivery system for estradiol/ progesterone. In: Zatuchni GI, Goldsmith A, Sciarra JJ (eds) Intrauterine contraception: advances and future prospects. Harper & Row, Philadelphia, pp 215–227
Glass R, Vessey M, Wiggins P (1974) Use-effectiveness of the condom in a selected family planning clinic population in the United Kingdom. Contraception 10 6: 591–598
Goldman JA, Dicker D, Feldberg D, Samuel N, Resnik R (1985) Barrier contraception in the teenager: a comparison of four methods in adolescent girls. Pediat Adolesc Gynecol 3 /1: 59–76
Goldman N, Pebley AR, Westoff CF, Paul LE (1983) Contraceptive failure rates in Latin America. [Summaries in SPA, FRE] Int Fam Plan Perspect 9 /2: 50–57
Goldzieher JW (1989) Pharmacology of contraceptive steroids: A brief review. Am J Obstet Gynecol 160/5 ii: 1260–1264
Goldzieher JW, Dozier TS, de la Pena A (1980) Plasma levels and pharmacokinetics of ethinyl estrogens in various populations. Contraception 21: 1–6
Gräfenberg E (1930) Die intrauterine Methode der Konzeptionsverhütung. Proceedings 3rd Sex Reform Congress, London
Gräfenberg E (1931) The intrauterine silver ring. In: Report of Int. World League for Sexual Reform. Kegan Paul, London
Graham S, Fraser I (1982) The progestogen-only mini-pill. Contraception 26: 373–388
Greenblatt RB, Cortés-Prieto J, Campos-da-Paz A (1980) The development of a new triphasic oral contraceptive. The Proceedings of a special symposium held at the 10th world congress on fertility and sterility, Madrid. MTP Press, Lancaster
Guillebaud J (1981) Missed pills — what advice should we give? Br J Fam Plann 7 /2: 41–44
Guillebaud J (1992) Choosing the right combined oral contraceptive for the individual woman. In: Newton JR, op ten Berg U (eds) Optimizing the estrogen dose in oral contraceptives. Parthenon, Casterton Hall, New Jersey, pp 17–32
Haberlandt L (1921) Über hormonale Sterilisierung des weiblichen Tierkörpers. MMW 68: 1877
Hafez ESE (1979) Human ovulation. Mechanism, prediction, detection and induction. Elsevier North-Holland, Amsterdam
Hafez ESE (ed) (1980) Human reproduction: conception and contraception. Harper & Row, Hagerstown
Hahn DW, Allen GO, McGuire JL (1977) The pharmacological profile of norgestimate, a new orally active progestin. Contraception 16: 541
Hammerstein J (1986) Einführung. In: Hammerstein J (Hrsg) 25 Jahre hormonale Kontrazeptiva aus Berlin. Excerpta Medica, Amsterdam
Hankinson E et al (1993) Tubensterilisation verringert das Risiko an einem Ovarialkarzinom zu erkranken. JAMA 270: 2813
Hansson V (1976) Regelmechanismen männlicher Fertilität. Sexualmedizin 2: 91–97
Harel L, Kaplan B (1993) Endometrial suction in luteal phase as a method of late postcoital contraception. Contraception 47: 469–474
Harlow BL et al (1988) Case-control study of borderline ovarian tumors: reproductive history and exposure to exogenous female hormones. Cancer Res 48: 5849–5852
Harris RWC, Brinton LA, Cowdell RH et al (1980) Characteristics of women with depplasia of carcinoma-in-situ of the cervix uteric. Br J Cancer 42: 359
Hartge P et al (1989) A case-control study of epithelial ovaria cancer. Am J Obstet Gynecol 161: 10–16
Hartmann M, Wettstein A (1934) Ein kristallisiertes Hormon aus Corpus luteum. Helv chim Acta 17: 878
Haukkamaa M, Allonen H, Heikkilä M, Luukkainen T, Lähteenmäki P, Nilsson CG, Toivonen J (1985) Long-term clinical experience with levonorgestrel-releasing IUD. In: Zatuchni GI, Goldsmith A, Sciarra JJ (eds) Intrauterine contraception: advances and future prospects. Harper & Row, Philadelphia, pp 232–237
Hellberg D, Valentin J, Nilsson S (1985) Long-term use of oral contraceptives and cervical neoplasia: an association confounded by other risk factors? Contraception 32: 337
Heller GCG, Clermont Y (1973) Spermatogenesis in men: an estimate of its duration. Science 140: 184–186
Henderson BE, Casagrande JT, Pike MC et al (1983) The epidemiology of endometrial cancer in young women. Br J Cancer 47: 749–756
Hildreth NG et al (1989) The risk of brest cancer after irridatiation of the thymus in infancy. N Engl J Med 321: 1281–1284
Hildreth NG et al (1981) An epidemiologic study of the epithelial carcinoma of the ovary. Am J Epidemiol 114: 398–405
Hoffmann KOK (1991) Normen und Qualitätsstandards für Kondome. Frauenärztliches Sem 6: 8
Hofmeister H, et al (1975) d15 —17a-Äthinylsteroide der Östranreihe. Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Präparate. DE 25 46 062. Berlin/Bergkamen: Schering AG
Hohlweg W, Junkmann K (1932) Die hormonal-nervöse Regulierung des Hypophysenvorderlappens. Klin Wo 11: 321–323
Hooper RR, Reynolds GH, Jones OG et al (1978) Cohort study of venereal disease. 1: The risk of gonorrhea transmission from infected women to men. Am J Epidemiol 108 /2: 136–144
Horwitz RI, Feinstein AR (1979) Case-control study of oral contraceptive pills and endometrial cancer. Ann of Intern Med 91: 226–227
Hulka BS, Chambless LE, Kaufman DG et al (1982) Protection against endometrial carcinoma by combination-product oral contraceptives. JAMA 247: 475–477
Inhoffen HH, Hohlweg W (1938) Neue per os-wirksame weibliche Keimdrüsenhormon-Derivate: 17-Aethinyloestradiol und Pregnen-in-on-3-o1–17. Naturwissenschaften 26: 96
Irwin KL et al (1988) Oral contraceptives and cervical cancer risk in Costa Rica: detection bias or causal association? Journal of the American medical Association 259: 59–64
Jain AK (1975) Comparative performance of three types of IUDs in the United States. In: Hefnawi F, Segal SJ (eds) Proceedings of the Third International Conference on intrauterin contraception, Cairo, Egypt, Dec. 12–14, 1974. Elsevier North-Holland, Amsterdam pp 3–16
Jain AK, Sivin I (1977) Life-wle analysis of IUP’s: problems and recommendations. Stud Fam Plann 8 /2: 25
Jones MW, Silverberg SG (1989) Cervical adenocarcinoma in young women: possible relationships to microgalandlär hyperplasia and use of oral contraceptives. Obstet Gynecol 73: 984–989
Joseph W, Goldzieher MD (1989) Pharmacology of contraceptive steroids: A brief review. Am J Obstet Gynecol 160: 1260–1264
Katznelson, S, Drew WL, Mintz L (1984) Efficacy of the Condom as barrier to the transmission of cytomegalovirus. J Infect Dis 150 /1: 155–157
Kaufman MS, Shapiro S, Slone D et al (1980) Decreased risk of endometrial cancer among oral contraceptive users. N Engl J Med 303: 1045–1047
Kaulhausen K (1977) Blutdruckkontrolle bei Einnahme hormo- naler Kontrazeptiva. Dtsch Ärzteblatt 45: 2695–2697
Kay C-R, Hannaford P-C (1988) Breast cancer and the pill. A furtherreport from the Royal College of General Practitioners, Oral Contraception Study. Br J Cancer 58: 675–680
Keep PA v, Davis KE, Wied D de (1987) Contraception in the Year 2001. Excerpta Medica, Amsterdam
Kelaghan J, Rubin GL, Ory HW, Layde PM (1982) Barrier-method contraceptives and pelvic inflammatory disease. JAMA 248 (20): 184–187
Kelsey JL, Hildreth NG (1983) Breast and gynecologic cancer epidemiology. CRC, Boca Raton
Kelsey JL, LiVolsi VA, Holford TR et al (1982) A case-control study of cancer of the endometrium. Am J Epidemiol 116:333–342
Key TJ, Pike MC (1988) The dose-effect relationship between unopposed oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer 57: 205–212
Kirkman RJE, Bounds W, Colliver D, Jackson R, Barden E (1992) Practical experience in the UK with an oestrogen/ progestogen contraceptive vaginal ring. Br J Fam Plann 18: 12–15
Kjaer A, Laursen K, Thormann L, Borggaard O, Lebech P-E (1993) Copper release from copper intrauterine devices removed after up to 8 years of use. Contraception 47 /4: 349–358
Knaus H (1933) Die periodische Fruchtbarkeit und Unfrucht- barkeit des Weibes. Zentralblatt Gynäkologie 57: 1393
Knuth UA, Behre H, Belkien L, Bents H, Nieschlag E (1985) Clinical trial of 10- nortestosterone-hexoxyphenylpropionate ( Anadur) for male fertilitiy regulation. Fertil Steril 44: 814
Koumantaki Y et al (1989) A case-control study of cancer of endometrium in Athens. International journal of cancer 43: 795 — 799
Krebs D (1992) Der Schwangerschaftsabbruch aus der Sicht des Gynäkologen. Forum „Ärzte und Juristen“ Frankfurt am 18.10.1991 im Rahmen der AWMF. Gynakol Geburtshilfe 1: 17–21
Kronmal RA, Whitney CW, Mumford SD (1991) The intrauterin device and pelvic inflammatory disease: the Women’s Health Study reanalyzed. J Clin Epidemiol 44: 109–122
La Vecchia C, Decarli A, Fasoli M et al (1986) Oral contraceptives and cancers of the breast and of the female tract. Interim results from a case-control study. Br J Cancer 54: 311–317
Lau H (1982) Indikationen zum Schwangerschaftsabbruch. Gesetz und Beratung der Konfliktschwangerschaft, 2. Aufl. Demeter, Gräfelfing
Laufs A (1989) Das Aufklärungsformular. Gynäkologe 22 /6: 363–368
Lauritzen C, Von de Graaf bis Pinkus und Rock: Die Geschichte der oralen hormonalen Kontrazeption in fünf Folgen von Prof. Dr. Christian Lauritzen, Ulm
Lauritzen C (1983) Persönliche Mitteilung
Lee Nc, Rubin GL, Borucki R (1988) The intrauterin device and pelvic inflammatory disease revisited: new results from the Women’s Health Study. Obstet Gynecol 72: 1–6
Levrier H (1983) Système endo-utérin contraceptif et thérapeutigue associant cuivre, argent, hormone naturelle et acede isoaminocaproique. Institut de la Propriété Industrielle, Paris, Patent No. 83.003.02, January 7, 1983
Li D-K, Daling JR, Stergachis AS, CHU J, Weiss NS (1990) Prior condom use and and risk of tubal pregnancy. Am J Public Health 80 /8: 964–966
Li XF, Newton J (1992) Progestogen only contraceptionand ectopic pregnancy. Br J Fam Plann 18: 70–84
LR Industries (1976) Contraception information service. The condom. United Kingdom use-effectiveness studies. London, LR Industries
Ludwig H (1976) Das Intrauterinpessar zur Kontrazeption. Wirkungsweise, Erfahrungen, Komplikationen. Geburtshilfe Frauenheilkd 36: 97–108
Makepeace AW, Weinstein GL, Friedmann MH (1937) Effect of progestin and progesterone on ovulation in the rabbit. Am J Physiol 119: 512–516
Mandelson MT et al (1990) Further evidence that duration and recency of oral contraceeptive use are associated with invasive cervical cancer. Presentation at the 23rd Annual Meeting of the Society of Epidemiology Research, Snowbird, UT, 12.15 June. Am J Epidemiol 132: 778
Mann RD (ed) (1990) Oral contraceptives and breast cancer. Parthenon, Casterton
Marrian GF (1929) The chemistry of östrin. Preparation from Urin and separatiom froman unidentified alcohol. Biochem. J 23: 1090
McCormack WM, Lee YH, Zinner SH (1973) Sexual experience and urehtral colonization with genital mycoplasmas: a study in normal men. Ann Int Med 78 /50: 696–698
McPherson K, Vessey M, Neil A et al (1987) Early oral contraceptive use and braest cancer: results of another case-control study. Brit J Cancer 56: 653–660
Meirik O, Lund E, Adami H-O et al (1986) Oral contraceptive use and breast cancer in young women. A joint national case-control study in Sweden and Norway. Lancet 2: 650–654
Miller N et al (1989) Histopathology of breast cancer in young women in relation to use of oral contraceptives. J Clin Pathom 42 /4: 387–390
Miller DR, Rosenberg L, Kaufman DW et al (1986) Breast cancer in relation to early oral contraceptive use. Obstet Gynecol 68: 863
Mills P-K et al (1989) Prospective study of exogenous hormone useand breast cancer in Seventh-Day-Adventists. Cancer 64: 591–597
Minuk GY, Bohme CE, Bowen TJ (1986) Condoms and hepati- tis B virus infection. Ann Int Med 104/4: 584 (Letter)
Molina R et al (1988) Oral contraceptives and cervical carcinoma in situ in Chile. Cancer Research 48: 1011–1015
Moyer DL, Shaw ST (1973) Intrauterine devices: biological action. In: Hafez ESE, Evans TN (Eds) Human reproduction: conception and contraception. Harper & Row, Hagerstown, pp 633–660
Moyer DL, Shaw ST Jr (1980) Mode of action of intrauterine devices. In: Hafez ESE (ed) Human reproduction: conception and contraception. Harper & Row, Hagerstown, pp 661–681
Muir C et al (1987) (eds) Cancer incidence in five continents, vol 5. IARC Sci Publ 88
Munoz N, Bosch FX (1989) Epidemiology of uterin cervical cancer. In: Munoz N et al (eds) Human papillomavirus and cervical cancer. IARC Sci Pubis 94: 9–39
Munoz N et al (1989) (eds) Human papillomavirus and cervical cancer. IARC Sci Publ 94
Newhouse ML, Pearson RM, Fullerton JM et al (1977) A case-control study of carcinoma of the ovary. Br J Prey Soc Med 31: 148–153
Newton J, Tacchi D (1990) Long-term use of copper intrauterin devices. Lancet 335: 1322–1323
Ngugi EN, Plummer FA, Simonsen JN et al (1988) Prevention of transmission of human immunodefiency virus in Africa: effectiveness of condom promotion and health education among prostitutes. Lancet 2 /8616: 887–890
Norplant-Produktinformation (1991) Laras, Turku, Finnland
Oberle MW, Rosero-Bixby L, Lee FK, Sanchez-Braverman M, Nahmias AJ, Guinan ME (1989) Herpes simplex virus type 2 antibodies: high prevalence in monogamous women in Costa Rica. Am J Trop Med Hyg 41 /2: 224–229
Oddens BJ, Vermer HM, Visser AP, Ketting E (1993) Contraception in Germany: a review. ADV-Contracept 9 /2: 105–116
Ogino K (1932) Über den Konzeptionstermin des Weibes und seine Anwendung in der Praxis. Zentralblatt Gynäkologie 56: 72
Ory HW (1974) Functional ovarian cysts and oral contraceptives: negative association confirmed surgicaly; a cooperative study. J Amer med Ass 228: 68–69
Ory HW et al (1977) Preliminary analysis of oral contraceptive use and risk of developing premalignant lesions of the uterin cervix. In: Garattini S und Berendes HW, ed. Pharmacology of steroid contraceptive drugs. New York, Raven Press pp. 211–218
Ory HW (1984) Oral contraception: Benefits and risks European Sterility Congress (VII.ESCO). Monte Carlo 23–26 September 1984 ESCO. NO. 7 (056)
Paul C, Skegg DCG, Spears GFS, Kaldon JM (1986) Oral contraceptive and breast cancer: a national study. Br Med J 293: 723
Parazzini F et al (1988) Risk factors for adenocarcinoma of the cervix: a case-control study. Br J Cancer 57: 201–204
Parazzini F et al (1990) Oral contraceptive use and invasive cervical cancer. Int J Epidemiol 19: 259–263
Parisot J (1987) Dein Kondom, das unbekannte Wesen. Kabel, Hamburg
Pearl R (1932) Contraception and fertility in 2000 women. Hum Biol 4: 363–407
Peel J (1972) The Hull family survey: 2. Family planning in the first 5 years of marriage. J Biosoc Sci 4 /3: 333–346
Peel JA (1969) Male-oriented fertility control experiment. Practitioner 202: 677–681
Pemberton J McCann JS Mahony JDH, Mackenzie G, Dougan H, Hay I (1972) Socio-medical characteristics of patients attending a V. D. clinic and the circumstances of infection. Br J Vener Dis 48 /5: 391–396
Persson E et al (1985) A case-control study of otal contraceptive use in women with adenocarcinoma of the uterin cervix. Eur J Obstet Gynecol and Reprod Biol 26: 85–90
Peritz E et al (1977) The incidence of cervical cancer and duration of oral contraceptive use. Am J Epidemiol 106: 462–469
Peters RK et al (1986) Increased frequency of adenocarcinoma of the uterine cervix in young women in Los Angeles country. JNCI 76: 423–428
Petterson B et al (1986) Menstruation span-a time limited risk factor for endometrial cancer. Act Obstet Gynecol-scand 65: 247–255
Piedrahita C, Hinson K, Foldesy R, Steiner M, Joanis C (1990) Latex condom breakage study Barbados and St. Lucia condom lot site. Family Health International (FHI). Research Triangle Park, North Carolina
Pike MC, Henderson BE, Casagrande JT et al (1981) Oral contraceptive use and early abortion as risk factors for breast cancer in young women. Br J Cancer 43: 72–76
Pike MC, Henderson BE, Krailo MD, Duke A (1983) Breast cancer in young women and use of oral contraceptives: possible modifying effect of formulation and age at use. Lancet IL: 926–929
Pincus G (1956) Some effects of progesterone and related compounds upon reproduction and early development of mammals. Proceed. V. International Conference Planned Parenthood, Tokyo. Acta Endocrinol (Copenh) 28: 18–36
Population Reports (1976) Sterilization. Tubal sterilization — review of methods. Popul Rep C 7, C-75, C-79, C-82, C-83, C-86, C-90
Population Reports (1978) Special topic monographs. Voluntary sterilization: world’s leading contraceptive method. Popul Rep [M] 2 /37
Population Reports (1979) Intrauterine devices. IUP’s — Update on safety, effectiveness and research. Popul Rep [B] 3 Population Reports ( 1982 ) Population and birth planning in the people’s Republic of China. Popul Rep [J] 25
Population Reports (1988) IUDs — a new look. Baltimore, Popul Rep [B] 5
Population Reports (1990) Condoms — now more than ever. Popul Rep [H] 8: 1–22
Potter RG (1976) Application of life-table techniques to measurement of contraceptive effectiveness. Demography 3: 297–304
Rabe T, Runnebaum B (1982) Kontrazeption. Springer, Berlin Heidelberg New York
Ramcharan S, et al (1981) The Walnut Creek contraceptive study. A prospective study of the side effects of oral contraceptives. Volume 3. Bethesda, National Institutes of Health (NIH Publikation No. 81–564 )
Ratnam SS, Singh K (1991) Towards safe motherhood. In: Teoh E-S, Ratnam SS (eds) The future of gynaecology and obstetrics. Parthenon, Casterton Hall
Ravnihar B et al (1988) A case-control study of breast cancer in relation to oral contraceptive use in Slovenia. Neoplasma 35: 109–120
Reeves WC, Brinton LA, Brenes MM et al (1985) Case-control study of cervical cancer in Herrera Province, Republic of Panama. Int J Cancer 36: 55
Rietmeijer CAM, Judson FN (1989) In vitro testing of condoms for prevention of HIV infection: a review. In: Alexander NJ, Gabelnick HL, Spieler JM (eds) Heterosexual transmission of AIDS. Proceedings of the Second Contraceptive Research and Development (Conrad) Program International Workshop, held in Norfolk, Virginia, Feb. 1–3, 1989. Wiley-Liss, New York, pp 355–363
Rietmeijer CAM, Krebs JW, Feorino PM, Judson FN (1988) Condoms as physical and chemical barriers against human immunodeficiency virus. JAMA 259 /12: 1851–1853
Riphagen FE (1987) Epidemiology of contraception with steroids in Western Europe. Wien Med Wochenschr 137/20–21: 488–491
Robertson WH (1990) An illustrated history of contraception. Parthenon, Casterton
Romieu I et al (1989) Prospective study of oral contraceptive use and risk of breast cancer in women. JNCI 81: 1313–1321
Rosenberg L, Shapiro S, Slone D et al (1982) Epithelial ovarian cancer and combination oral contraceptives. JAMA 247: 3210–3212
Rosenberg M, Hill HA, Friel PA (1990) Spermicides and condoms for the prevention of HIV and other sexually transmitted diseases. Presented at Strategies for Viricide Research Meeting, World Health Organization, Mar. 28, 1990. WHO, Geneva
Rosenberg MJ, Davidson AJ, Chen J-H, Judson, FN, Douglas, JM (1991) The effect of barrier contraceptives on sexually transmitted diseases in women: a comparison of female-dependent methods with condoms. (Unpublished)
Roumen FJME, Bouckaert PXJM (1989) Contraception using a vaginal ring releasing 3-keto-desogestrel and ethinylestradiol. Recent developments in fertility and sterility series. Parthenon, Casterton, pp 79–81
Royal College of General Practitioners (1974) Oral contraception and health; an interim report from the oral contraception study of the Royal College of General Practitioners. Pitnam, New York, p 71
Royal College of General Practitioners (1981) Further analyses of mortality in oral contraceptive users. Lancet 1: 541–546
Runnebaum B, Rabe T, Kiesel L (ed) (1991) Female contraception and male fertility regulation. Parthenon, Casterton
Ruzicka L, Wettstein A (1935) Künstliche Herstellung des männlichen Sexualhormons trans-Dehydroandrosteron and des
Androsten-3, 17-dions. Helv Chim Acta 28:986–994
Russo J et al (1990) Biology of disease. Comparative study of human and rat mammary tumorgenesis. Lab-Invest. 62 /3: 244–278
Sam AP (1992) Controlled release contraceptive devices: a status report. J Controlled Release 22: 35–46
Schindler AE, Dennemark N, Herold J et al (1990) Contraception with a vaginal ring containing an estrogen/progestogen combination. A German multicenter study. In: Runnebaum B, Rabe T (eds) Female contraception and male fertility regulation. Parthenon, Casterton, pp 131–134
Schlesselmann JJ (1991) Oral contraeptives and neoplasia of the uterin corpus. Contraception 43: 557–579
Schlesselmann JJ et al (1988) Breast cancer in relation to early use of oral contraceptives: no evidence of a latent effect. JAMA 259: 1828–1833
Schreiner WE (1976) Ovar. In: Siegenthaler W (Hrsg) Klinische Pathophysiologie, 3. Aufl. Thieme, Stuttgart, S 390
Schreiner WE (1986) Komplikationen der Tubensterilisation. Ther Umschau, 43 /5: 425–433
Schwartz SM, Weiss NS (1986) Increased incidence of adenocarcinoma of the cervix in young women in the United states. Am J Epidemiol 124: 1045–1047
Schwartz SM et al (1989) A case-control study of risk factors for sarcomas of the uterus. Cancer 64: 2487–2492
Segal SJ, Alvarez-Sanchez F, Adejuwon CA et al (1985) Absence of chorionic gonadotropin in sera of women who use intrauterin devices. Fertil Steril 44: 214–218
Semm K, Giese K-P (1981) Ernst Gräfenberg, das Leben und Werk des Kieler Facharztes. Zum 100. Geburtstag am 26. Sept. 1981. Geburtshilfe Frauenheilkd 41: 397–460
Shaw ST (1981) Eur. Patent Office. Nos. 0.024.779 Al; 0.024.780 Al; and 0.024.781 Al, March 11, 1981
Shu XO et al (1989) Population-based case-control study of ovarien cancer in Shanghai. Cancer Res 49: 3670–3674
Siboulet A (1972) Maladies sexuelles transmissibles: Intérêt des traitements prophylactiques. [Sexually transmitted diseases: importance of prophylactic treatment.] [FREI Prophylaxie Sanitaire et Morale 44 /5: 155–159
Sivin I (1979) Measuring contraceptive efficiency and side effects. J Gynecol Obstet 16: 460–465
Sivin I (1989) IUDs are contraceptives, not abortifacients: a comment on research and belief. Stud Fam Plann 20: 355–359
Sivin I, Stern J (1979) Long-acting, more effective copper T IUDs: a summary of U. S. experience, 1970–1975. Stud Fam Plann 10:1263 —1281
Sivin I, Stern J, Couthino E et al (1991) Prolonged intrauterin contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg20) and the copper T380 Ag IUDs. Contraception 44: 473–480
Slattery ML, Overall JC, Abbott TM, French TK, Robison LM, Gardner J (1989) Sexual activity, contraception, genital infections, and cervical cancer: Support for a sexually transmitted disease hypothesis. Am J Epidemiol 130 /2: 248–258
Smith H, Hughes GA, Douglas GH et al (1964) Totally synthetic steroid hormones. Part 2:13-beta-alkyl-gona-1,3 5)10)trienes, 13beta-alkylgon 4-en-3-ones, and related compounds. L Chem Soc 4: 4472–4479
Snowden R (1977a) The statistical analysis of menstrual bleeding patterns. R Biosoc Sci 9: 107–120
Snowden R (1977b) The progestasert and ectopic pregnancy. Br Med J II: 1600–1601
Sparks RA, Purrier BGA, Watt PJ, Elstein M (1981) Bacteriological colonisation of uterine cavity; role of tailed IUD. Br Med J 282: 1189–1191
Spicer DV, Pike MC, Pike A, Rude R, Shoupe D, Richardson J (1993) Pilot trial of a gonadotropin hormone agonist with replacement hormones as a prototype contraceptive to prevent breast cancer. Contraception 47: 427–444
Stadel BV, Rubin GL, Webster LA et al (1985) Oral contraceptives and breast cancer in young women. Lancet 2: 970–973
Stanford JL (1991) Oral contraceptives and neoplasia of the ovary. Contraception 43: 543–556
Swan SH, Brown WL (1981) Oral contraceptive use, sexual activity and cervical carcinoma. Am J Obst Gynecol 139: 52–57
Talwar GP (1990) Zwei Impfstoffe in klinischer Prüfung zur Fertilitätskontrolle und zur Behandlung von hormonabhängigen Karzinomen des Genitaltraktes. Presented at: Internationales Symposium: New aspects in female contraception/ recent advances in the regulation of male fertility, Heidelberg 1990
Tatum HJ (1977) Clinical aspects of intrauterine contraception. Circumspection 1976. Fertil Steril 28 /1: 3–28
Tatum HJ (1983) Milestones in intrauterine device development. Fertil Steril 39: 141–143
Tatum HJ, Connell EB (1986) A decade of intrauterine contraception: 1976–1986. Fertil Steril 46: 173–192
Tausk M, Thijssen JHH, Wimersma Gredanus TjB van (1986) Pharmakologie der Hormone, 4. Aufl. Thieme, Stuttgart, 122–145
Taylor-Papadimitriou J (1990) Immunohistochemical analysis of benign and malignant breast tumours. Pathol-Biol 38 /8: 778
Tejuja S, Saxena NC, Malhotra U, Choudhury SD (1975) Experience with the copper T in India. In: Hefnawi F, Segal S (eds) Analysis of intrauterine contraception. Elsevier/North Holland, Amsterdam, p 165
Thiery M, van der Pas H, van Os WA et al (1978) Three years experience with a multiload Cu 250, a new copper-wired intrauterine contraceptive device. Adv Plann Parent 13: 35
Thomas DB (1989) The breast. In: Mchal F (ed) Safety requirements for contraceptive steroids. Cambridge University Press, Cambridge, pp 38–68
Thomas DB (1991) Oral contraceptives and breast cancer: a review of the epidemiologic literature. Contraception 43: 597–642
Tietze C (1960) Probability of pregnancy resulting from a single unprotected coitus. Fertil Steril 11 /5: 485–488
Tietze C, Lewit S (1962) Intra-uterine contraceptive devices. Proceedings of the Conference on intra-uterine contraceptive Devices, New York, April/May 1962. Int Congr Ser 54. Excerpta Medica Foundation, Amsterdam
Tietze C, Potter RG (1967) Recommended procedures for statistical analysis of clinical data on intrauterine devices. Stud Fam Plann 18: 1
Tietze C, Lewit S (1970) Evaluation of intrauterine devices: Ninth progress report of the Cooperative Statistical Program. Stud Fam Plann 55: 1–40
Tietze C, Lewit S (1979) Mortality and fertility control. Int J Gynecol Obstet 16: 456–459
Timonen H, Luukkainen T (1974) The use-effectiveness of the copper T-200 in a simulated field trial. Contraception 9: 1–13
Trapido E-J-A (1981) Aprospective cohort study of oral contraceptives and breast cancer. JNCI 67: 1011–1015
Trussell J, Kost K (1987) Contraceptive failure in the United States: a critical review of the literature. Stud Fam Plann 18 /5: 237–283
Tzonou A et al (1984) The epidemiology of ovarian cancer in Greece: a case-Control study. Eur J Cancer Clin Oncol 20: 1045–1052
U.K. National Case-control Study Group (1989) Oral contraceptive use and breast cancer risk in in young women. Lancet 1: 973–982
United Nations Department of International Economic and Social Affairs (1989) Levels and trends of contraceptive use as assesst in 1988 ST/ESA/Ser.A/110.UN Publication, No. E. 89. XIII: 4
United States, Centres for Disease Control (1987) Antibody to human immunodeficiency virus in female prostitutes. MMWR 36 /11: 157–161
van den Broeck AJ, van Bokhoven C, Hobbelen PMJ, Leemhuis J (1975) 11-Alkylicene steroids in the 19-nor series. Reel Tray Chim Paus Bas Belg 94: 35
Vessey MP (1983) Contraception and benign breast disease-epidemiological studies. In: Renand R, Gairard B (eds) Contraception et Sein. Masson, Paris, p 63
Vessey MP (1990) The Jephcott Lecture 1989. An overview of the benefits and risks of combined oral contraceptives. In: Mann RD (ed) Oral contraceptives and breast cancer. Parthenon, Casterton Hall, pp 121–135
Vessey MP, Thorogood M (1989e) Patterns of oral contraceptive use in the United Kingdom. Br J Rheumatol 28 [Suppl]: 46–47
Vessey MP, Yeates D, Flavel R, Mc Pherson K (1981) Pelvic inflammatory disease and the intrauterin device: findings in a large cohort study. Br Med J 282: 855–857
Vessey MP et al (1983) Neoplasia of the cervix uteri and contracepton: a possible adverse effect of the pill. Lance 2: 930–934
Vessey MP et al (1987) Ovarian neoplasma, functional ovarian cysts, and oral contraceptives. Br Med J 294: 1518–1520
Vessey MP (1989) Oral contraception and cancer. In: Filshie M, Guillebaud J (eds.) Contraception: Science and Practice, pp. 52–68 ( London: Butterworth )
Vessey MP, Villard-Mackintosh L, McPherson K, Yeates D (1989a) Mortality among oral contraceptive users: 20 year follow up of women in a cohort study. Br Med J 299: 1487–1491
Vessey MP et al (1989b) Oral contraceptives and breast cancer: latest findings in a large cohort study. Br J Cancer 59: 613–617
Voeller B, Coulson AH, Bernstein GS, Nakamura RM (1989) Mineral oil lubricants cause rapid deterioration of latex condoms. Contraception 39 /1: 95–102
Wang MW, Sims MJ, Heap RB, Taussig MJ (1990a) Prevention of pregnancy with immunization with anti-idiotype against a monoclonal anti-progesteron antibody. Dept Immunology, AFRC Institut of Animal Physiology and Genetics Research, Babraham, Cambridge CB2 4AT, United Kingdom
Wang MW, Sims MJ, Symington PR, Humphreys AS, Taussig MJ (1991) Induction of anti-progesteronr immunity and pregnancy blocking by anti-progesterone anti-idio types. Variable efficacy of polyclonal Ab2 antibodies directed against apanel of closely related Abi antibodies. Immunology 73 /3: 348–355
Wang SX, Luo AM, Liang ZG, Song JF, Wang HA, Chen YX (1990b) Preparation and characterization of monoclonal antibodies against sperm-specific lactat dehydrogenase C4. J Androl 11 /4: 319–324
Weiss NS et ai (1980) Incidence of endometrial cancer in relation to the use of oral contraceptives. N Engl J Med 302: 551–554
Weiss NS, Lyon JL, Liff JM et al (1981) Incidence of ovarian cancer in relation to the use of oral contraceptives. Int J Cancer 28: 669–671
WHO (1987) Mechanism of action, safety and efficacy of intrauterin devices. WHO Techn Rep Ser 753: 91
WHO Collaborative Study of Neoplasia and Steroid Contraceptives (1990) Breast cancer and combined oral contraceptives: results from a multinational study. British journal of cancer 61: 110–119
WHO (1985) Collaborative Study of Neoplasia and Steroid Contraceptives. Invasive cervical cancer and combined oral contraceptives. Br Med J 290: 961–965
WHO (1988) Collaborative Study of Neoplasia and Steroid Contraceptives. Endometrial cancer and combined oral contraceptives. International journal of epidemiology 17: 263–269
WHO (1989) Collaborative Study of Neoplasia and Steroid Contraceptives. Epithelial ovarian cancer and combined oral contraceptives. Int J Epidemiol 18: 535–545
WHO (1992a) Development and assessment of fertility regulation technologies. Biennial Report 1990–1991. WHO, Geneva
WHO (1992b) Prevention of infertility. Biennial Report 1990–1991. WHO, Geneva
WHO (1992e) Expanding family planning options through the systematic introduction and appropriate management of contraceptive methods. Biennial Report 1990–1991. WHO, Geneva
WHO (1992d) Epidemiological research in reproductive health. Biennial Report 1990–1991. WHO, Geneva
WHO (1992e) Oral contraceptives and Neoplasia. WHO Technical Report Series 817. WHO, Geneva
WHO (1993) Menstrual blood loss with use of a vaginal ring releasing 20 µg Levonorgestrel per day. Contraception 47: 455–468
Wiechert R (1977) Fertilitätskontrolle als Beitrag zum Überleben der Menschheit. Angew Chem 89: 513
Wiechert R, Neumann R (1965) Gestagene Wirksamkeit von 1-Methyl-und 1,2 Alpha-Methylen-Steroiden. Arzneimittelforschung 15: 244
Wildemeersch D (1984) Procédé et dispositif de fixation à la matrice, au cours de la période du post-partum immédiat, d’un dispositif anticonceptionnel intra-utérin. Ministère des Affaires Economiques, Bruxelles. Brevet d’Invention No. 899–286 (A 61F/A 61B)
Wildemeersch D (1985) Dispositif anticonceptionnel intra-utérin nouveau et perfectionné, et son dispositif d’insertion et de fixation à la matrice. Ministère des Affaires Economiques, Bruxelles. Brevet d’invention No. 901. 652 (A 61F)
Willett WC, Bain C, Hennekens CH et al (1981) Oral contracep- tives and risk of ovarien cancer. Cancer 48: 1648–1687
Winkelstein W (1990) Smoking and cervical cancer-current status: a review. Am J Epidmiol 131: 945–957
Wu ML et al (1988) Personal and environmental characteristics related to epithelial ovarian. I. Reproductive and menstrual events and oral contraceptive use. Am J Epidemiol 128: 1216–1227
Yolles S (1982) United States Patent No. 4. 344–431
Yuzpe AA, Smith RP, Rademaker AW (1982) A multicenter clinical investigation employing ethinyl estradiol combined with dl-Norgestrel as a post-coital contraceptive agent. Fertil Steril 3 7: 508–513
Zanartu J, Dabances A, Oberti C, Rodriguez-Brovo R, GarciaHuidobro M (1977) Low-dose oral progestogens to control fertility: I. clinical investigation. Obstet Gynecol 43: 87–96
Ziel HK (1982) Estrogen’s role in endometrial cancer. Obstetrics Gynecol 60: 509–515
Rights and permissions
Copyright information
© 1994 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Rabe, T., Runnebaum, B., Kellermeier-Wittlinger, S. (1994). Kontrazeption. In: Gynäkologische Endokrinologie und Fortpflanzungsmedizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-07635-4_13
Download citation
DOI: https://doi.org/10.1007/978-3-662-07635-4_13
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-07636-1
Online ISBN: 978-3-662-07635-4
eBook Packages: Springer Book Archive